News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

All
News
Press Releases
News

From The Lab To The Clinic: Developing And Delivering The Next Generation Of Therapies To Patients In Need

December 6, 2024

Forbes Healthcare Summit

Read Now
News

Scribe Therapeutics Verifies In Vivo CRISPR-Based Cardiometabolic Therapies

November 27, 2024

Inside Precision Medicine

Read Now
News

The 2024 PharmaVoice 100

October 8, 2024

PharmaVoice

Read Now
News

Engineering The Future Of Genetic Medicine

September 10, 2024

Progress, Potential, and Possibilities

Read Now
News

Leadership essentials: “Inspire, motivate, and cultivate”

September 9, 2024

BigThink

Read Now
News

Small Enzymes, Giant Leaps: CRISPR’s Next-Generation Approach to Genetic Diseases

August 5, 2024

BioSpace

Read Now
Press release

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Read Now
Press release

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

May 16, 2023

Read Now
Press release

Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 2, 2023

Read Now
Press release

Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 31, 2023

Read Now
Press release

Scribe Therapeutics to Participate in Four Upcoming Conferences

November 17, 2022

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 29, 2022

Read Now

Publications